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Implication statement: Safe anesthetic care necessarily requires access to controlled 
medicines, which are often unavailable in low- and middle-income countries. This article 
reviews pertinent national and international barriers to accessing controlled medicines 
and aims to improve anesthesiologists’ understanding of how to strengthen global periop-
erative care.  
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Abstract 
Purpose: This article  describes the functioning of the international drug control 
system, its integration into national legislation and policy, and the collective impact 
on access to medicines.   
 
Source: We conducted a review of the three international drug control conventions, 
peer-reviewed articles and grey literature known to the authors that describes na-
tional and international drug control systems and their impact on access to con-
trolled medicines. This was supplemented with literature derived from a structured 
search of MEDLINE for articles related to medical uses of ketamine in low- and mid-
dle-income countries, conducted to strengthen an advocacy campaign. We illustrate 
the impact of the drug control system on access to medicines through an analysis of 
current levels of availability of opioids in many countries, as well as through a de-
scription of the ongoing advocacy work to ensure the availability of ketamine for 
medical care in low-income countries.  
 
Principal Findings: The complexity of the international drug control system, and 
health providers’ lack of knowledge regarding key provisions, presents a barrier to 
improving access to safe anaesthetic care in low- and middle-income countries. Fif-
teen  of the 46 essential medicines of potential relevance to perioperative care are 
listed under one or more of the schedules of the three international drug control 
conventions and are, subsequently, required to be under national controls, poten-
tially decreasing their availability for medical use.   
 
Conclusion: Improving the capacity and quality of anesthetic care in low- and mid-
dle-income countries requires attention to improving access to controlled medi-
cines. Anesthesiologists and others involved in global health work should collabo-
rate with policymakers and others to improve national and international drug con-
trol legislation to ensure that attempts to thwart illicit drug trafficking and use do 
not compromise availability of controlled medicines. 
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Introduction  
 
  It is estimated that up to 313 million surgical procedures are performed annually 
worldwide, of which only approximately 6% occur in low- and lower-middle-income 
countries (as defined by the World Bank), though they are home to 37% of the world’s 
population.1–3 Estimates of the global burden of disease treatable by surgery vary signifi-
cantly, and few studies provide population-level surveys or data. The estimates that do 
exist, however, suggest that surgical conditions (including common conditions such as 
trauma, malignancies, congenital anomalies, complications of pregnancy, cataracts, and 
perinatal conditions) comprise between 11-32% of the global burden of disease.4–6 These 
data demonstrate that the low volume of surgical procedures performed in low-income 
countries does not correspond to the need. Rather, a significant gap in access to surgery 
exists with over 5 billion people lacking access to safe, affordable surgical and anesthetic 
care. To fill this gap, an additional 143 million procedures per year would need to be con-
ducted to save lives and prevent disability.2  
 
 Provision of safe surgical care requires access to safe anesthesia. Unfortunately, 
the availability of anesthetic care is hindered by a lack of trained providers, anesthetic 
equipment, basic infrastructure, and essential medicines. Attempts to quantify these gaps 
have revealed an anesthetic workforce that is up to a hundred times smaller per capita in 
low-income versus high-income countries, with grossly insufficient access to basic equip-
ment such as pulse oximetry, and anesthetic medicines.5–8  
 
To better understand the reasons for the global surgery gap, we propose examin-
ing one of the likely drivers of poor access to anesthetic care: access to controlled medi-
cines. Many commonly used anesthesia medicines, such as potent analgesics, hypnotics, 
and others, are essential to the provision of anesthetic and perioperative care and pain 
management. However, recent estimates suggest that roughly 5.5 billion people, or three 
quarters of the world’s population, live in countries with very-low, or non-existent, access 
to opioid analgesics.8 This critical deficit is likely an important contributor to the global 
surgical gap.9 We say “likely” because we are aware of no empirical studies that demon-
strate this gap. The authors’ and others’ abundant experience, however, suggests that an-
esthetic medicines are often in short supply in developing countries, and that controlled 
medicines such as morphine are frequently unavailable or under-utilized.  
 
 There have been few, if any, attempts to systematically understand the unique 
drivers of poor access to pharmaceutical products for anesthetic care in low- and middle-
income countries (LMIC).10 Despite this, several reports have documented poor availabil-
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ity of many anesthetic medicines, and data on the global availability of controlled medi-
cines demonstrate poor (and in some cases, almost wholly absent) access predominantly 
in low- and middle-income countries, with multiple systemic barriers.11,12 Simply put, 
why is access to controlled medicines such a global failure, even in countries where there 
are celebrated and successful campaigns to improve access to medicines for other condi-
tions, such as for the “big three” of HIV/AIDS, malaria and tuberculosis?  
 
The answer is not intellectual property (or patents), though this is often said to be the ma-
jor barrier to acquiring medicines at affordable prices. Of the anesthetics and analgesics 
present on the World Health Organization’s (WHO) Model List of Essential Medicines 
(EML), none has a currently valid patent, and many (such as morphine) are older medi-
cines that can be manufactured and sold relatively inexpensively as generics.13,14 A more 
likely explanation for this lack of access is that many of these medicines are controlled 
under national and international law, which together constitute a barrier to reliable access, 
and may explain both documented and anecdotal accounts of poor access to and use of 
anesthetics and analgesics in surgical programs in developing countries.  
 
Many essential medicines related to perioperative care are listed in one of the schedules 
of the three United Nations (UN) based international drug control treaties and controlled 
under national schedules (Table 1). Barriers to accessing controlled medicines, which in-
clude medicines for anesthesia, perioperative analgesia, palliative care, and even epi-
lepsy, are rooted in a byzantine regulatory system that prioritizes restricting access to il-
licitly trafficked substances, over ensuring licit access to medicines. The cultural narra-
tive and policy focus on the abuse potential of “drugs” trumps the valid medical uses of 
those same substances, and results in non-availability in the vast majority of low- and 
middle-income countries. 
 
  In this narrative review, we propose that the control systems themselves foster 
unduly restrictive laws, and that their complexity perpetuates providers’ lack of under-
standing and misinterpretations about the rational use of controlled medicines. To explain 
this hypothesis, we provide an overview of international and national drug control sys-
tems, focusing on controlled medicines, and how national and international laws and reg-
ulations contribute to restricting their availability. To illustrate how the international drug 
control system can potentially have a disastrous impact on safe anesthesia, we summarize 
a current and ongoing campaign to oppose attempts to place ketamine under more restric-
tive international controls.  
 
The International Drug Control System  
 A suite of three multilateral treaties forms the basis of the international drug con-
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trol system: the 1961 Single Convention on Narcotic Drugs (as amended by the 1972 Pro-
tocol), which focuses primarily on plant based substances such as opium, cannabis, and 
cocaine; the 1971 Convention on Psychotropic Substances, which focuses on synthetic 
and non-plant based drugs including amphetamines, barbiturates and tranquilizers; and 
the 1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psy-
chotropic Substances, which concentrates on the illicit trafficking of substances listed in 
the schedules of both its sister treaties, as well as on precursor substances.15 The genesis 
of these three treaties predates the 1961 Single Convention, which, as the name suggests, 
brought together a series of treaties that were developed since the first multilateral instru-
ment addressing the drug issue, the 1912 International Opium Convention, was drafted. 
Initially concerned primarily with limiting the growing opium trade, these pre-war trea-
ties addressed among other issues the non-medical trade in, diversion from pharmaceuti-
cal sources to illicit markets, and consumption of cocaine, heroin, and morphine.16 
 
 Two UN bodies oversee the implementation of the three conventions. The Com-
mission on Narcotic Drugs (CND) (comprised of 53 member states) is the central policy-
making body of the United Nations drug control system, and the International Narcotics 
Control Board (INCB) is the 'quasi-judicial body' responsible for monitoring and enforc-
ing member states’ implementation of the treaties. The United Nations Office on Drugs 
and Crime (UNODC) is the executive agency responsible for coordinating international 
drug control activities, and serves as the secretariat of the Commission on Narcotic 
Drugs. Figure 1 illustrates the various entities involved in drug control.  
 
Substances under international control are listed under one of four schedules ap-
pended to each of the international treaties (hence the term “scheduling”. Unlike the 
1961 and 1971 Conventions, the 1988 Trafficking Convention has a system of two 
'tables' under which substances are classified).  The CND alone does not have the au-
thority to add a new substance to a schedule. The treaties require that the World Health 
Organization’s Expert Committee on Drug Dependence (ECDD) which conducts a thor-
ough, evidence-based review following the request (called a notification) of a state party 
(a signatory to the relevant treaty) to review a substance. This process may also be initi-
ated by the WHO itself. The ECDD review concludes with a recommendation either not 
to schedule, or to place the substances in one of the four schedules.  
 
The ECDD, which is comprised of a diverse group of experts in pharmacology, 
clinical medicine, and other relevant disciplines, ensures at least in theory that the medi-
cal benefits of a substance are properly weighed against the public health or safety rea-
sons to restrict or ban it. The Director General of the WHO then conveys the ECDD rec-
ommendation to the CND, which is bound to accept the recommendation of the WHO on 
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medical and scientific matters. The CND, however, may take other circumstances into ac-
count, such as legal and economic factors, when it votes on whether to place a substance 
under control. This flexibility has been contested and is discussed in the context of the re-
cent proposal to place ketamine under international control. The intent of the scheduling 
process is to strike a balance by placing the substance within a continuum ranging from 
outright prohibition to varying degrees of restriction (which may involve no international 
controls at all).  Each of the different schedules in the treaties reflects a stage in this con-
tinuum. Table 2 provides the criteria for each schedule under each treaty.    
 
 Scheduling a substance that has legitimate medical and scientific uses, however, 
poses its own difficulties. The Conventions establish an awkward mandate for countries 
to both restrict unlicensed access to such substances by regulating their manufacture, dis-
tribution, and possession, while also recognizing that the same controlled substances have 
legitimate scientific or medical uses for the relief of suffering. This vague double impera-
tive has been interpreted as establishing a requirement to strike a balance between control 
and provision, yet the operational paragraphs of the Conventions provide no requirements 
or recommendations to states on how to properly ensure access to medicines and balance 
these mandates (yet contain several operational requirements on how to restrict access). 
 
For example, while the Single Convention stipulates specific regulatory actions to 
restrict unlicensed access to narcotics, it is silent regarding the regulatory provisions nec-
essary to advance legitimate scientific and medical access to substances under control. 
The result has been that countries over-emphasize criminal prohibition and under-empha-
size, or entirely ignore, the need to provide access to scheduled medicines. Even the lead-
ership of the INCB acknowledges this imbalance, and recent statistical modelling has 
shown that although consumption of opioid analgesics has more than doubled worldwide 
between 2001 and 2013, most of this increase has occurred in North America, western 
and central Europe, and Oceania, with countries in other regions (Africa, Asia, Central 
America, the Caribbean, South America, and eastern and southeastern Europe) showing 
no substantial increase in use.12,17 
 
 As non-self-executing treaties, the Conventions only establish a binding frame-
work that signatories must then operationalize under their own domestic legal systems. 
Thus, while the Conventions represent an agreement on the controls deemed appropriate 
amongst member states, national authorities must translate this into national legislation 
specific to each country, for example the 1971 Misuse of Drugs Act in the United King-
dom,18 the 1970 Controlled Substances Act in the United States,19 and the 1996 Con-
trolled Drugs and Substances Act in Canada.20  
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 The Single Convention also establishes a system of import and export controls de-
signed to limit and monitor the international trade of licit controlled narcotics. This sys-
tem obliges governments to authorize and/or license any entities that participate in the 
trade or distribution of these medicines, including pharmaceutical companies, distribu-
tors, and pharmacists. Each transaction has to be recorded in detail, and all transactions 
are subject to a quota imposed on each country by the INCB as a result of that country’s 
annual provision of estimates of the quantities of controlled medicines required. Coun-
tries must also provide quarterly data on imports and exports of narcotic drugs.  All this 
documentation is onerous, especially for less developed countries, and can significantly 
impact the availability of opioid analgesics. 
 
 For example, the Single Convention requires countries to submit estimates of their 
annual requirements for controlled medicines, which establishes the quantity of these 
medicines that each country can legally import in the coming year. The INCB is sup-
posed to confirm the estimates are reasonable, given the Single Convention’s dual man-
date, but in practice the INCB frequently confirms estimates that are well below what 
could reasonably be presumed to be the actual medical need based on the burden of dis-
ease. This is arguably because of a lack of capacity within countries to properly estimate 
their annual requirements and a lack of capacity within weak health systems to properly 
manage pain. The confirmation of unrealistically low estimates by the INCB is, at best, 
questionable. At worst, it is a violation of their treaty-mandated role to ensure that parties 
comply with the aims of the convention, one of which is to ensure adequate access.  
 
Chad, for example, is allocated 61 grams of fentanyl, 160 grams of morphine, 35 
grams of codeine, and 1 gram of normethadone for a country of 13.5 million people.21 
This compares to Canada, whose consumption of controlled medicines is among the 
highest in the world and is allowed 59 controlled substances, including 150,000 grams of 
fentanyl, 4,000,000 grams of morphine, 33,392,500 grams of codeine, and 20,000 of nor-
methadone for a population that is slightly more than twice that of Chad. This disparity in 
access is arguably multifactorial, and previous studies have demonstrated barriers includ-
ing an absence of awareness or training in the use of opioid medicines, fears of addiction, 
issues in sourcing from industry or imports, and other systemic barriers that need to be 
addressed.12 This should include, but goes beyond, the INCB’s status of estimates system.  
 
After the INCB confirms the estimates, states have to comply with other complex 
bureaucratic requirements, particularly for medicines included in the schedules of the 
1961 Convention. For each shipment of medicines, the importing country must issue an 
import license to a pharmaceutical supplier, who must send the license to the competent 
authorities in the exporting country. The competent authorities verify its authenticity, 
sometimes by contacting the INCB, and decide whether the importing country remains 
 10 
within the quota established through the confirmed estimates. A single mistake can result 
in having to repeat the entire process, which several organizations have highlighted as the 
cause of delays of months to years in obtaining single shipments of controlled medicines 
such as morphine or pethidine.22 
 
 Similar requirements exist for the substances controlled under the 1971 Conven-
tion on Psychotropic Substances.23 In general, the 1971 Convention is less stringent, due 
in large part due to political maneuvering during the drafting and negotiation of the 
treaty. This process was driven by the high income countries of the ‘Global North’ who 
lobbied for less stringent controls on behalf of their domestic pharmaceutical industries, 
and preferred to maintain access to synthetic medicines such as benzodiazapines, rather 
than plant-based materials such as opium or cannabis.24 
 
Thus the treaties have explicitly set up barriers to access to medicines containing 
controlled substances, barriers that have no parallel in public health.  While many other 
prescription medicines have bad, or arguably worse, public health effects if abused (e.g. 
antibiotics and antimicrobial resistance), only narcotics and psychotropic medicines are 
subject to the degree of reporting required by these treaties. For less developed countries 
and health systems plagued by chronic human and physical resource shortages, the work-
flow of tracking all the controlled substances entering or circulating in the country is ef-
fectively an impossible task and an error may result in severe criminal punishment. As a 
result, providers must function with negligible access to these and other essential anes-
thetic medicines, or must risk being non-compliant, a risk few are willing to take.   
 
National Scheduling of Medicines 
 The Conventions could be viewed as a set of minimum standards for drug control, 
whereby countries must meet a baseline set of obligations. However, the national legisla-
tion of many countries actually exceeds these standards. A recent review of legislation in 
11 Central and Eastern European countries, for example, identified legal barriers in the 
prescribing of opioids in all of the nations studied, while 10 countries included dispensing 
barriers and used stigmatizing language to describe controlled medicines.25 This included 
language that overemphasized the addictive nature of opioids or severely restricted phar-
macists’ ability to dispense medications, for example restricting the dispensing of opioids 
prescribed by physicians from a different city.  
 
 Furthermore, there are often discrepancies between international scheduling re-
quirements and national legislation. Although both the 1971 and 1961 Conventions both 
contain four schedules, national drug control laws may not offer similar degrees of nu-
ance. Kenya, for example, has only three schedules, each one providing only one level of 
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control for narcotic drugs, psychotropic substances, and prohibited plants.26 Thus, alt-
hough the intention of international scheduling is to provide some nuance and gradients 
in the restrictions imposed upon essential medicines, the treaties do not require parties to 
reproduce these nuances at the national level.  
 
 Restrictive national laws and policies with devastating effects have been docu-
mented in several countries. In Ukraine, Human Rights Watch documented a grossly in-
adequate and cumbersome system that restricted access to effective palliative care for ter-
minally ill patients in pain.27 This included policies that prohibited patients who were not 
receiving curative care from being admitted to hospital and required healthcare workers 
to directly administer opioid medications to patients (rather than leaving a supply for pa-
tients or families to administer). Because of a lack of oral morphine in the country, 
healthcare workers were required to travel to patients’ homes six times a day to adminis-
ter injectable morphine, a requirement that was near impossible to meet, resulting in an 
unnecessary barrier to effective pain relief for patients with moderate to severe pain.  
 
In a related publication, Human Rights Watch found that Armenian domestic legislation 
allows only cancer patients to receive opioids as outpatients.28 Only oncologists are al-
lowed to prescribe, and prescriptions require the approval of a standing commission com-
prised of the patient’s oncologist, the chief and/or deputy chief doctor of one of the 13 
polyclinics authorized to prescribe opioids, the chief nurse, general practitioner, and 
sometimes up to two other physicians in the polyclinic. Additional requirements include 
the use of a special government approved form that must be stamped by four involved 
physicians and clinics.28 Although anesthesiologists help train oncologists in pain man-
agement, they are not allowed to prescribe opioids to outpatients.  
 
India provides an example of how restrictive national laws can be reformed, although it is 
too soon to determine how effective these reforms have been in improving availability. 
India’s earlier previous narcotics control law, the Narcotic Drugs and Psychotropic Sub-
stances (NDPS) Act of 1985, instituted excessively burdensome licensing procedures for 
accessing opioid analgesics.29 Each state had different rules requiring pharmacists and 
doctors to procure four to five different licenses before they could prescribe or dispense 
morphine to patients. These licenses required the approval of multiple government de-
partments, and each needed to be valid at the same time. Even minor errors in bookkeep-
ing could result in significant penalties. Following ratification of the 1985 Act (which In-
dia had to promulgate in order to comply with the provisions of the Single Conven-
tion), the consumption of morphine in the country dropped from an already low level of 
573 kg in 1985, to 17 kg in 1997.30  
 
Concerted and vigorous pressure from civil society ensured that the NDPS Act was 
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subsequently reformed in 2014, shifting the power for the legislating control of opi-
oid analgesics from the states to the central government. Now  health providers 
need only a single governmental approval from a single agency is necessary to for 
procure and dispense morphine.31 The amended Act is applicable but has not yet 
reached the implementation stage throughout the country. Hence, many states con-
tinue to have the 5 license requirements and the punishment for an error (e.g. even 
one license beyond the expiry date is still harsh - 10 years in prison). Moreover, 
there is no proportionality in punishment for the alleged crime: a discrepancy of few 
milligrams of opioid medicine stock in a hospital is equivalent to possession of a few 
kilograms of an illicitly trafficked substance for the purpose of criminal proceedings. 
 
 We are unaware of a systematic analysis of the impact of national drug control 
policies on access to anesthetics and analgesics in hospital settings. The impact of these 
policies on community- or primary-care settings, particularly for palliative care, have 
been well-described;32 the impact on the availability of medicines in hospitals with surgi-
cal capacity is less clear, though several analyses have documented shortages of essential 
anesthetics, including controlled medicines, in hospital settings.33–37 Further research is 
needed to determine the cause of anesthetic medicine stock-outs, though in surveys of an-
esthetic and surgical capacity, several note that narcotic analgesics are infrequently, or 
never, available, further suggesting that the barriers to accessing controlled medicines 
differ from non-controlled medicines. These barriers to access need to be further explored 
to determine where the barriers exist, including examining what barriers exist at the pro-
vider, health system, and legislative levels.  
 
Recent Experiences with a Proposal to Schedule Ketamine 
Ketamine is an N-methyl-D-aspartate receptor antagonist that is commonly used 
around the world for anesthesia, procedural sedation, and acute and chronic pain con-
trol.38 It is a particularly useful medication as it provides dissociative anesthesia and anal-
gesia without a significant loss of airway protection, respiratory drive or cardiovascular 
stability; it also has a wide therapeutic index.39,40 In many operating rooms in low-income 
countries, there is no physician anesthetist present; instead, ketamine anesthesia is often 
administered by a nurse, operating room assistant, or even by the surgeon who is simulta-
neously performing the operation.41–43 Because of its unique properties and broad range 
of applications, ketamine is listed on the World Health Organization’s Model List of Es-
sential Medicines.14 
 
Many hospitals in LMICs lack both mechanical ventilators and sophisticated 
monitoring equipment.44 The cardiovascular stability and relatively intact respiratory 
drive under ketamine anesthesia make it possible to use this medication without a me-
chanical ventilator and even when only minimal monitoring is available.45 For example, a 
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recent survey in Mongolia determined that only 1 in 5 hospitals routinely employ periop-
erative capnography.46 In cases of extreme resource shortages such as disaster relief ef-
forts, equipment can be even more limited.  Healthcare workers indicated that during the 
response to the 2010 earthquake in Haiti, some emergency procedures under ketamine se-
dation were monitored with just “chest excursion, color, carotid pulse, and manual arte-
rial blood pressure measurement”.42 Thus, the good safety profile of ketamine makes it 
indispensable in these resource-limited settings. A recent review of a ketamine anesthesia 
protocol in rural hospitals by non-physician anesthesia providers examined 193 consecu-
tive surgical procedures. They identified no major adverse events and only a small num-
ber of minor adverse events (brief desaturation of <30 seconds in 8.6% of patients and 
hallucinations in 12.1%), providing further evidence of the utility of this medicine in safe 
anesthetic care in resource-limited settings.47 
 
In addition to its safety profile, ketamine is an affordable generic medicine.  It is 
portable and stable, which make it practical for use in remote areas and disaster relief ef-
forts.48 In a campaign supported by the World Federation of Societies of Anesthesiolo-
gists, frontline healthcare workers have repeatedly noted the crucial role of ketamine in 
providing life-saving procedures in LMICs;49 this sentiment was echoed by the ECCD, 
which stated that reducing the availability and accessibility of ketamine “in turn would 
limit access to essential and emergency surgery, which would constitute a public-health 
crisis in countries where no affordable alternative anesthetic is available”.50  
 
 Many of the properties that make ketamine useful as an anesthetic also make it 
appealing as a recreational hallucinogen. Ketamine has long been recognized as a drug of 
misuse, with reports of recreational use appearing in the medical literature shortly after its 
introduction into medical practice in the 1970s.51–53 In this regard, the drug produces ef-
fects that are similar to other psychedelic drugs, specifically phencyclidine, or PCP, of 
which ketamine is a derivative, though it has a briefer duration of action than most other 
drugs such as lysergic acid diethylamide (LSD).54 Non-medical use appears to be particu-
larly widespread in South-East Asia, especially in China.55 
 
 The International Narcotics Control Board and several member states have re-
sponding to this non-medical use by calling for the CND to place ketamine under interna-
tional control. In 2004, despite arguably exceeding its mandate, the INCB asked the “in-
ternational community to give serious consideration to initiating the procedure” for plac-
ing ketamine under international control, and also called on the WHO to expedite its 
ECDD review of the medicine.56 This growing momentum, fueled in large part by the 
INCB and several member states, has by-and-large ignored the impact that scheduling 
would have on access to ketamine for medical use in low-income, low-resource settings. 
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This process has been controversial, because ketamine is an essential medicine whose ab-
sence in anesthetic carts would place millions of the world’s poorest patients in the cruel 
position of having to choose between foregoing surgical procedures due to lack of anes-
thetic, or undergoing surgery without it. Furthermore, the UN drug control agencies have 
been marginalizing the WHO, whose treaty based role is crucial and has direct bearing on 
global health, particularly with regard to the 1971 Convention on Psychotropic Sub-
stances.57  
 
In 2014, the government of China notified the Secretary-General of the United 
Nations to recommend that ketamine be placed in Schedule I of the 1971 Conven-
tion.58,59 This followed the passage of a non-binding resolution proposed by Thailand and 
passed by vote of the member states at the 2014 Commission on Narcotic Drugs calling 
for member states to pursue national scheduling. The impact of this resolution was miti-
gated by statements of several key member states that opposed listing ketamine under in-
ternational schedules out of concern that doing so would restrict medical access.60 Fol-
lowing China’s notification that it intended to pursue international scheduling of keta-
mine, the ECDD conducted a third review of the medicine. It once again recommended 
against scheduling due to a lack of evidence of widespread, international misuse suffi-
cient to balance against the restrictions that would be imposed on medical availability of 
the drug, likely limiting its use in anesthetic practice. The review was externally peer-re-
viewed by experts, with one reviewer warning that scheduling would create a “global 
public health crisis” should ketamine become unavailable as the anesthetic of necessity in 
resource-poor settings.50 This ECDD review was subsequently updated in November 
2015 and similar recommendations were made.  
 
The 1971 Convention states that WHO has sole authority to make determinations 
as to whether there is sufficient evidence “…warranting the placing of [a] substance un-
der international control,” in a medical and scientific context, notes that on these matters, 
WHO’s “assessments shall be determinative.”61 The ECDD has reviewed ketamine four 
times, including an update in November 2015, and has repeatedly found that scheduling 
of ketamine would not be appropriate. The WHO has communicated this to the CND, and 
given that placing restrictive international controls on an essential medicine used to pro-
vide basic surgical care to billions in poor countries is clearly a medical issue, WHO’s 
decision should have been final. However, the CND, acting on legal advice provided by 
the UNODC, still initiated the scheduling process by placing it on the agenda of the 
CND, arguing that it may consider economic, social, legal, administrative and other fac-
tors it deems relevant. This position remains controversial.  
 
China initially requested ketamine be listed as a Schedule I substance, which by 
definition refers to a substance with no legitimate medical or scientific use and, therefore, 
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requires the imposition of stringent restrictions. This was a remarkable proposal given the 
medicine’s widespread and diverse therapeutic uses. In response, a significant interna-
tional challenge was mounted by the global anesthesia, surgery, and veterinary medicine 
communities, supported by numerous health and human rights organizations to oppose 
this proposal.62–66 The resultant effect was dramatic, including a widely disseminated and 
broadly endorsed fact sheet on ketamine,67 and several member states actively opposed 
the Chinese proposal. In the end, China relented, initially altering its proposal to list keta-
mine under the less restrictive Schedule IV, rather than Schedule I,68 and finally opting to 
defer the vote to a later date, likely because of an obvious lack of support for the pro-
posal. The possibility of pursuing the scheduling of ketamine still remains, and the matter 
is not closed, though in November 2015 the WHO Expert Committee on Drug Depend-
ence once again updated its review of ketamine and reaffirmed its decision that it not be 
placed under international control.69  
The subject re- emerged at the regular session of the 59th Commission on Nar-
cotic Drugs in 2016, with China once again proposing to defer a decision as to whether to 
place ketamine under international control, meaning that the notification remains alive 
and could be pursued with little notice at subsequent sessions. Furthermore, although 
there was no explicit proposal on the agenda to place ketamine in one of the international 
schedules, the Chinese delegation attempted to include references to ketamine in a resolu-
tion calling for voluntary controls on new psychotropic substances.  The resolution in-
cluded language urging pre-export and other controls on states parties, thereby introduc-
ing something close to 'scheduling by resolution' -  a backdoor mechanism of restricting 
access and one that lies outside the provisions of the international drug control conven-
tions.  China’s attempt to include ketamine in the resolution ultimately failed, thanks to 
strong resistance from the same member states that opposed the formal measure in 2015. 
 
The mechanics of this scheduling proposal and subsequent campaign are com-
plex, and grounded in international drug control law – unfamiliar territory for many anes-
thesiologists and health professionals.59 Yet, it highlights the importance of an elemen-
tary understanding of international and national scheduling and the need to maintain an 
active voice in these international fora that have the potential to drastically impact on the 
delivery of safe anesthetic care for billions in low-income countries.  
 
Discussion 
 Significant disparities remain in accessing safe and effective surgical care, with 
the world’s poorest being disproportionately disadvantaged by low levels of service 
availability. Addressing this disparity requires coordinated action to ensure that safe sur-
gery and anesthesia are no longer neglected as essential health services.70 There are signs 
that this is changing: the World Health Assembly, in 2015, passed resolution 68.15, rec-
ognizing the importance of surgery and anesthesia as a component of universal health 
 16 
coverage, which was a significant political advance.71 Realizing the impact of this resolu-
tion, however, will require significant movement on the ground to comprehensively and 
sustainably integrate surgical services into health systems in low-income countries, for 
which there is little guidance.10 A key component of this will be to ensure the reliable 
availability of high-quality anesthetic and analgesic medicines.   
 
Anesthesia is uniquely affected by national and international drug control laws, 
with 15 of the 46 anesthesia and analgesia-related essential medicines listed in the cate-
gories of: Anaesthetics, Medicines for Pain and Palliative Care, or Anticonvulsants/an-
tiepileptics (all of which have some crossover into clinical anesthesia) also being under 
international control through one of the three drug control conventions (table 1).14,15 Alt-
hough the availability of medicines is obviously inseparable from the practice of anesthe-
sia, relatively little work has been done to document the availability of both controlled 
and uncontrolled anesthetics and the barriers to obtaining them in health systems in low-
income countries. A recent systematic review of the integration of surgical care into 
health systems identified a lack of medicines for surgical care as a concern, but provided 
no analysis of the reasons for the poor availability.10 
 
Ensuring access to these medicines should, therefore, be a foundational compo-
nent of programs to improve the availability of surgery and anesthesia in low-income 
countries. Without the availability of high-quality anesthetics and analgesics, the scaling-
up of global surgical capacity is near-impossible.  
 
It is important to recognize that the restrictions that result from national and inter-
national controls (“scheduling”) of medicines are feasible and reasonable in many high-
income countries for controlling inappropriate access to substances with the potential to 
produce harm, and the judicious and responsible use of controlled medicines is essential. 
However, these restrictions must be reasonable and must ensure the appropriate availabil-
ity of medicines under national or international control. Several high-income countries 
have placed ketamine under national control with no apparent systemic adverse effects 
for appropriate medical access, though it must also be recognized that, in contrast with 
the situation in low-income countries, ketamine is not the anesthetic agent of choice or 
necessity in most circumstances in high-income countries. However, currently, controlled 
medicines are disproportionately inaccessible in low- and middle-income countries rela-
tive to uncontrolled medicines and relative to high-income countries with competent and 
functioning regulatory systems. Complying with the regulatory requirements of these na-
tional and international systems are onerous, and given that most controlled medicines 
are older generic medicines for which profit margins are generally small, the costs associ-
ated with compliance are proportionally significant, and likely serves as a deterrent to 
many companies who may simply withdraw products from markets rather than shoulder 
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the costs and burdens of compliance. At present, there does not appear to be a model of 
how to place a medically-necessary substance under national or international control 
while simultaneously ensuring its rational availability for medical purposes in low- and 
middle-income countries, despite the fact that such a balance is the intention of the inter-
national drug control regime and the conventions on which it is founded. 
 
 The barriers to accessing adequate pain management, however, do not reside ex-
clusively in regulatory or legislative systems. Health professionals require the knowledge 
and training to successfully implement these interventions into patient care in low-in-
come countries, and significant work remains to be done to counter false or exaggerated 
perceptions of the harms associated with opioid analgesic use and to ensure that pain 
management is consistently provided as part of perioperative care, and that the medicines 
to do so are consistently and appropriately available.72 
 
The experience, knowledge and awareness gained by the global anesthesia com-
munity by opposing the ketamine scheduling proposal should be but a starting point for 
addressing the broader access constraints plaguing anesthesia and surgical providers and 
patients in low-income countries. This experience points to the need for the anesthesia 
community to serve as advocates for access to essential medicines and to more compre-
hensively understand how existing systems impact on the availability of anesthetics and 
the delivery of patient care.  
 
Conclusions and future directions 
 The inadequate treatment of pain for over 5 billion people is arguably one of the 
greatest tragedies in global health. While substantial work has been done to understand 
and address the barriers to accessing analgesics for palliative care, little work has been 
done to improve access to controlled medicines for anesthesia. As global surgery gains 
momentum with national governments, international donors, and aid organizations, there 
is an urgent need to ensure that anesthesia providers advocate for access to essential med-
icines. This includes campaigning to redress the barriers to accessing controlled medi-
cines, which form a sizable proportion of the medicines used in the provision of clinical 
anesthesia. The anesthesia community has not had a presence at important moments in 
controlled medicine policy, such as the Commission on Narcotic Drugs or the United Na-
tions General Assembly Special Session on Drugs, but should. Anesthesia providers 
should have a strong, visible presence at international drug control meetings, and should 
work with other medical communities who have been active in this area, specifically pal-
liative care, to ensure that national and international drug control policies place a strong 
emphasis on access to controlled medicines to improve the availability and quality of safe 
anesthetic care for patients in low- and middle-income countries.   
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Table 1 – Anesthetic and Analgesic Medicines Under International Control* 
Medication International Treaty Control 
Cocaine SCND (Schedule I) 
Codeine SCND (Schedule II) 
Clonazepam CPS (Schedule IV) 
Diazepam CPS (Schedule IV) 
Ephedrine* CAITNDPS (Table I) 
Ergotamine CAITNDPS (Table I) 
Fentanyl SCND (Schedule I) 
Lorazepam CPS (Schedule IV) 
Methadone* SCND (Schedule I) 
Midazolam CPS (Schedule IV) 
Morphine SCND (Schedule I) 
Oxycodone* SCND (Schedule I) 
Phenobarbital CPS (Schedule IV) 
Remifentanyl SCND (Schedule I) 
Sufentanyl SCND (Schedule I) 
 
Medicines highlighted in green are also listed on the World Health Organization’s 19th 
Model List of Essential Medicines. *listed as an alternative or complementary medication 
on Model List. SCND = Single Convention on Narcotic Drugs, CPS = Convention on 
Psychotropic Substances, CAITNDPS = Convention Against Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances 
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Table 2 – Definitions of Controlled Substance Schedules24,73 
 
1961 Single Convention on Narcotic Drugs 
Schedule I Substances that are highly addictive and liable to abuse, or are con-
vertible into drugs that are similarly addictive and liable to abuse 
Schedule II Substances that are less addictive and liable to abuse than those in 
Schedule I 
Schedule III Preparations containing narcotic drugs that are intended for medi-
cal use and are unlikely to be abused 
Schedule IV Certain drugs listed in Schedule I that are highly addictive and lia-
ble to abuse and rarely used in medical practice 
Schedule V Substances that have a low potential for abuse relative to sub-
stances listed in Schedule IV and consist primarily of preparations 
containing limited quantities of certain narcotics 
1971 Convention on Psychotropic Substances 
Schedule I Substances presenting a high risk of abuse, posing a particularly 
serious threat to public health, which are of very little or no thera-
peutic value 
Schedule II Substances presenting a risk of abuse, posing a serious threat to 
public health, which are of low or moderate therapeutic value 
Schedule III Substances presenting a risk of abuse, posing a serious threat to 
public health, which are of moderate or high therapeutic value 
Schedule IV Substances presenting a risk of abuse, posing a minor threat to pub-
lic health, with a high therapeutic value 
1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances 
Table I Precursors of psychotropic substances and key reagents use in the 
conversion and extraction of narcotic drugs and psychotropic sub-
stances 
Table II Reagents and solvents which can be used in the illicit production of 
narcotic drugs and psychotropic substances, but also have wide-
spread industrial uses 
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Figure 1 – Entities in the United Nations Drug Control System 
 
 
INCB = International Narcotics Control Board, UNODC = United Nations Office on Drugs 
and Crime.  
